Sharemaestro Newsreel

Haemonetics (HAE) Q1 2027 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8 a.m. ET CALL PARTICIPANTS Vice President, Investor Relations and Treasurer - Olga GuyetteChief Executive Officer - Christopher SimonChief Financial Officer - James D'Arecca TAKEAWAYS Net Revenue -- $339.4 million, representing 5.6% reported …

Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More

This article details Wall Street analyst upgrades, downgrades, and initiations for various companies on Thursday, August 13, 2026, following the release of inline CPI data. Key movements include Five Below being upgraded to Buy at Jefferies and StubHub being cut to Underperform at Bank …

Earnings Update: Quanterix Corporation (NASDAQ:QTRX) Just Reported And Analysts Are Trimming Their Forecasts

Quanterix Corporation recently reported disappointing second-quarter results, with revenues falling 12% short of analyst estimates and statutory losses significantly exceeding expectations. Following this, analysts have made serious cuts to their revenue outlook for 2026, now expecting a 6.8% decline, and anticipate increased losses per …

CONMED (NYSE:CNMD) Upgraded to Hold at Zacks Research

Zacks Research has upgraded CONMED (NYSE:CNMD) from a "strong sell" to a "hold" rating, despite the broader analyst consensus remaining at "Reduce" with an average price target of $41.40. This upgrade follows CONMED's strong quarterly earnings report, where it exceeded EPS and revenue estimates, …

NeuroOne(R) Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9%

NeuroOne Medical Technologies Corporation reported strong fiscal Q3 2026 financial results, with product revenue increasing 16% year-over-year to $2.0 million and gross margins expanding to 59.9%. The company also announced $2.7 million in new product orders, received ISO 13485 Certification for international expansion, and …

GE HealthCare Technologies (NASDAQ:GEHC) Stock Rating Upgraded by Zacks Research

Zacks Research upgraded GE HealthCare Technologies (NASDAQ:GEHC) stock from "strong sell" to "hold." This upgrade aligns with a broader analyst consensus of "hold" and a target price of $77.73, following the company's strong quarterly earnings report where it surpassed EPS expectations and saw a …

QRG Capital Management Inc. Buys 198,951 Shares of Boston Scientific Corporation $BSX

QRG Capital Management Inc. significantly increased its stake in Boston Scientific Corporation (NYSE:BSX) by 121.5% in the second quarter, acquiring 198,951 additional shares and bringing its total holdings to 362,716 shares valued at $15.5 million. This comes amidst strong financial performance from Boston Scientific, …

Wasatch Advisors LP Buys 186,357 Shares of OrthoPediatrics Corp. $KIDS

Wasatch Advisors LP significantly increased its stake in OrthoPediatrics Corp. (NASDAQ:KIDS) by 56.6% in the second quarter, purchasing an additional 186,357 shares. This brings their total holdings to 515,677 shares, representing 2.01% of the company. OrthoPediatrics recently reported better-than-expected earnings, with a smaller loss …

Lumexa Imaging Holdings, Inc. Stock 12‑Month Price Target Cut to $16.43, Implies 40% Upside

The average 12-month price target for Lumexa Imaging Holdings, Inc. (LMRI) stock has been reduced by analysts from $17.29 to $16.43, despite still implying a 40% potential upside based on the latest closing price. Eight analysts maintain a "Buy" consensus rating for the company, …

Insulet Corporation (PODD) Stock forecasts

Argus has lowered its target price for Insulet Corporation (PODD) to $159.00 from its previous rating. Insulet, founded in 2000, aims to simplify continuous subcutaneous insulin infusion therapy for diabetes. The stock's current price is $144.68.

V. M. Manning & CO. Inc. Acquires New Position in Abbott Laboratories $ABT

V. M. Manning & CO. Inc. has acquired a new stake in Abbott Laboratories, purchasing 19,849 shares valued at approximately $1.8 million, making it their 11th largest holding. This move comes as Abbott Laboratories exceeded its quarterly earnings expectations and maintains a positive outlook …

Wasatch Advisors LP Has $20.49 Million Stock Position in TransMedics Group, Inc. $TMDX

Wasatch Advisors LP reduced its stake in TransMedics Group (NASDAQ:TMDX) by 10.9% in the second quarter but still holds 308,434 shares valued at $20.49 million. The company's recent earnings showed a revenue beat but an EPS miss, leading to mixed analyst ratings with an …

MaxCyte, Inc. $MXCT Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC significantly increased its stake in MaxCyte, Inc. (NASDAQ:MXCT) by 153.3% in the first quarter, acquiring an additional 1.206 million shares to own a total of 1.993 million shares, representing 1.86% of the company. Other institutional investors also built positions, with hedge …

Earnings call transcript: BrainsWay tops revenue forecasts in q2 2026

BrainsWay Ltd. reported strong second-quarter 2026 results, exceeding revenue forecasts with $17.1 million and matching adjusted EPS expectations at $0.07. The company raised its full-year 2026 revenue guidance to $68 million-$70 million, driven by strong demand for its Deep TMS systems and SWIFT accelerated …

Wasatch Advisors LP Sells 1,897,237 Shares of Cerus Corporation $CERS

Wasatch Advisors LP reduced its stake in Cerus Corporation by 35.9% in the second quarter, selling 1,897,237 shares but still retaining 3.38 million shares valued at approximately $9.9 million. Cerus reported quarterly revenue of $63.3 million and an adjusted loss of $0.01 per share, …

Western Wealth Management LLC Has $1.77 Million Stock Position in Medtronic PLC $MDT

Western Wealth Management LLC significantly increased its stake in Medtronic PLC by 271.2% in the first quarter, now holding 20,382 shares valued at $1.77 million. Medtronic maintains a "Moderate Buy" consensus among analysts with an average price target of $98.83, following solid Q1 earnings …

Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Consensus Rating of "Reduce" from Brokerages

Boston Scientific Corporation $BSX Shares Purchased by Fisher Funds Management LTD

Fisher Funds Management LTD significantly increased its stake in Boston Scientific Corporation (NYSE:BSX) by 17.1% in the second quarter, bringing its total holding to approximately $43 million. This comes as institutional investors collectively own 89.07% of BSX. Boston Scientific recently reported strong quarterly revenue …

Brookstone Capital Management Sells 233,448 Shares of Boston Scientific Corporation $BSX

Brookstone Capital Management significantly reduced its stake in Boston Scientific, selling 233,448 shares and retaining a smaller position. Despite this sale, institutional investors still hold a large percentage of the company, and analysts maintain a "Moderate Buy" rating. Boston Scientific recently surpassed quarterly earnings …

Renaissance Technologies LLC Trims Position in Delcath Systems, Inc. $DCTH

Renaissance Technologies LLC reduced its stake in Delcath Systems (NASDAQ:DCTH) by 57.1% in the first quarter, selling over 200,000 shares but still retaining a significant holding. Despite this, other institutional investors have increased their positions. The company reported strong Q1 revenue and earnings, surpassing …

Dimensional Fund Advisors LP Reduces Position in Inogen, Inc $INGN

Dimensional Fund Advisors LP significantly reduced its stake in Inogen, Inc. by 28.3% in the first quarter, selling over 200,000 shares but still retaining a substantial holding. Despite this reduction, other institutional investors have increased their positions, and Inogen's stock holds a "Moderate Buy" …

Price to sales forward of MaxCyte, Inc. – MUN:MYE0

This page from TradingView provides financial information for MaxCyte, Inc. (MUN:MYE0), specifically focusing on its forward price-to-sales ratio. The article indicates that market data is provided by ICE Data Services and reference data by FactSet, with SEC filings from Quartr.

Haemonetics Corporation (NYSE:HAE) Receives Average Rating of "Moderate Buy" from Analysts

Haemonetics Corporation (NYSE:HAE) has received a consensus "Moderate Buy" rating from eleven research firms, with an average 12-month price target of $90.89. The company recently surpassed quarterly expectations, reporting $1.14 EPS and $339.38 million in revenue, leading several analysts to raise their price targets …

Lumexa outlines $235M-$241M 2026 adjusted EBITDA amid Hospital for Special Surgery joint venture expansion

Earnings Call Insights: Lumexa Imaging Holdings, Inc. (LMRI) Q2 2026 MANAGEMENT VIEW * CEO Caitlin Zulla said, "Q2 was a quarter of substantial progress as we continue to execute against the strategic priorities," and highlighted "driving strong same-center growth with an expanding mix of …

Boston Scientific Corp (BSX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Boston Scientific Corp (BSX), detailing its current price momentum score, support and resistance levels, and various technical indicator readings. It also includes an analysis of moving averages and addresses frequently asked questions regarding technical ratings and moving …

Rep. Mike Kelly Unloads Abbott Laboratories (NYSE:ABT) Shares

Representative Mike Kelly sold shares of Abbott Laboratories (NYSE:ABT) valued between $1,001 and $15,000 on July 17th, as well as shares of PepsiCo and Walt Disney on the same day. This sale occurred despite Abbott Laboratories reporting a quarterly earnings beat and reaffirming its …

Zimmer Biomet reports strong second quarter financial results

Zimmer Biomet Holdings Inc. announced strong financial results for the second quarter of 2026, with net sales increasing by 4.8% to $2.177 billion and adjusted diluted earnings per share at $2.07. The company is raising its revenue and adjusted EPS guidance for the year …

Glaukos (GKOS) Is Up 6.7% After Raising 2026 Sales Guidance And Narrowing Quarterly Loss

Glaukos (GKOS) shares rose 6.7% after the company increased its 2026 net sales guidance to US$680 million to US$700 million and narrowed its quarterly loss per share to US$0.31. This positive adjustment follows strong Q2 2026 sales of US$185.61 million and the introduction of …

MaxCyte Q2 Results: EPS beats estimates, revenue falls 14.5% YoY

MaxCyte Inc. reported Q2 2026 results, with EPS beating estimates at $(0.08) despite a 14.53% year-over-year revenue decrease to $7.271 million. The company narrowed its net loss by 33.33% and announced a new strategic partnership with Genentech. MaxCyte also reaffirmed its full-year 2026 revenue …

MaxCyte Inc (MXCT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Enterprise ...

MaxCyte Inc. reported a 15% decrease in total revenue for Q2 2026, reaching $7.3 million, with core revenue down 21%. Despite this, the company exceeded expectations and highlighted significant growth in CASGEVY royalties and a new enterprise-level partnership with Genentech to diversify revenue streams. …

Revisiting Former Stock Picks Medtronic, Quantas Services, Lennar

Reassessing stock picks is one of the best habits an investor can build. Watch Doug discuss recent stock picks, provide input on the current market environment—and take your questions. The daily chart illustrates how well the stock has performed relative to its peers on …

STERIS (STE) Could Be 10% Undervalued Following Strong Results And $600 Million Expansion

QuidelOrtho (QDEL) Stock Sees Fair Value Cut As Analysts Rework Growth Expectations

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. The sharp reset in QuidelOrtho's fair value estimate from US$20.50 to US$12.00 per share sits alongside analyst price targets that now cluster around the US$12 …

Globus Medical (GMED) Stock Sees Modest Fair Value Cut As Analysts Trim Growth Views

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Globus Medical has seen its assessed fair value cut from US$107.42 to US$103.23, a modest 3.9% trim that reflects a cooler view on …

Insulet Deadline: PODD Investors with Losses in Excess of $100K Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit

The Rosen Law Firm reminds investors who purchased Insulet Corporation (NASDAQ: PODD) securities between February 21, 2025, and May 26, 2026, of the August 31, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Insulet made false and misleading statements …

Is Globus Medical (GMED) A Bargain On Its Zacks Upgrade And Reaffirmed Guidance?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Globus Medical (GMED) has been in focus after a recent upgrade to Zacks Rank #1, which came shortly after the company reaffirmed its …